Modality
Radioligand
MOA
GLP-1ag
Target
C5
Pathway
Incretin
Ewing Sarcoma
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Mar 2031
Phase 2Current
NCT04855789
2,326 pts·Ewing Sarcoma
2020-11→2031-03·Recruiting
NCT03476152
310 pts·Ewing Sarcoma
2022-05→2025-12·Active
2,636 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-024mo agoPh2 Data· Ewing Sarcoma
2031-03-195.0y awayPh2 Data· Ewing Sarcoma
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Recruit…
P2
Active
Catalysts
Ph2 Data
2025-12-02 · 4mo ago
Ewing Sarcoma
Ph2 Data
2031-03-19 · 5.0y away
Ewing Sarcoma
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04855789 | Phase 2 | Ewing Sarcoma | Recruiting | 2326 | PFS |
| NCT03476152 | Phase 2 | Ewing Sarcoma | Active | 310 | 6MWD |
Competitors (10)